165,916 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Jump Financial LLC

Jump Financial LLC bought a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 165,916 shares of the company’s stock, valued at approximately $1,314,000. Jump Financial LLC owned 0.05% of Amneal Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMRX. XTX Topco Ltd increased its stake in shares of Amneal Pharmaceuticals by 75.8% during the fourth quarter. XTX Topco Ltd now owns 39,055 shares of the company’s stock valued at $309,000 after acquiring an additional 16,845 shares during the period. Mariner LLC increased its position in shares of Amneal Pharmaceuticals by 3,749.1% during the 4th quarter. Mariner LLC now owns 424,291 shares of the company’s stock valued at $3,360,000 after purchasing an additional 413,268 shares during the period. Barclays PLC raised its stake in shares of Amneal Pharmaceuticals by 18.9% in the 4th quarter. Barclays PLC now owns 352,494 shares of the company’s stock worth $2,792,000 after buying an additional 56,110 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth $2,946,000. Finally, Martingale Asset Management L P lifted its holdings in shares of Amneal Pharmaceuticals by 56.4% in the fourth quarter. Martingale Asset Management L P now owns 149,648 shares of the company’s stock valued at $1,185,000 after buying an additional 53,944 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the completion of the sale, the director now directly owns 1,888,886 shares of the company’s stock, valued at approximately $15,375,532.04. This represents a 4.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This trade represents a 9.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,160,000 shares of company stock valued at $43,113,200 over the last quarter. Company insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Trading Up 2.5 %

Shares of AMRX opened at $7.36 on Friday. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.18 and a 1-year high of $9.48. The stock has a market capitalization of $2.28 billion, a P/E ratio of -10.82 and a beta of 1.06. The business’s 50-day moving average price is $8.10 and its 200 day moving average price is $8.24.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The firm had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. During the same quarter in the prior year, the firm earned $0.14 EPS. On average, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Wall Street Analyst Weigh In

AMRX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Barclays boosted their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, March 3rd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Buy” and an average target price of $10.80.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.